[Urinary biomarkers of kidney injury in patients treated with anti-VEGF drugs].

Background: Antiangiogenic drugs are widely used in oncological practice and are aimed at inhibiting angiogenesis. Despite the high antitumor efficacy, their use may be limited by nephrotoxicity, and therefore the search for early biomarkers of kidney damage remains relevant, which will preserve a favorable safety profile of therapy.

Aim: To determine urinary biomarkers of tubular and podocyte damage in patients receiving treatment with antiangiogenic drugs.

Early biomarkers of nephrotoxicity associated with the use of anti-VEGF drugs.

Anti-angiogenic anticancer drugs that block vascular endothelial growth factor (VEGF) can cause kidney damage. An early assessment of the risk of nephrotoxicity would allow the development of optimal treatment approaches and allow for relatively safer therapeutic regimens. The aim of this study was to assess the utility of neutrophilic gelatinase-associated lipocalin (NGAL), kidney injury molecule 1 (KIM-1), hypoxia inducible factor-1α (HIF-1α) and nephrin levels in urine as early biomarkers for the nephrotoxicity of anti-VEGF drugs.

[Clinical and laboratory signs and risk factors for nephrotoxicity, associated with antiangiogenic drugs].

Background: Anti-angiogenic anticancer drugs that block the vascular endothelial growth factor signaling pathway can cause renal damage. Assessment of the risk of nephrotoxicity allows developing optimal treatment approaches and ensuring the relative safety of therapy.

Aim: To assess early clinical and laboratory manifestations and risk factors for nephrotoxicity of antiangiogenic drugs.

[Nephrotoxicity of anti-angiogenesis drugs].

Neoangiogenesis is a basic factor for most physiological as well as pathological processes i.e. tumor metastases.